Nearly 50 per cent patients at Rajdhani Covid-19 Hospital SGPGIMS have been found to have diabetes as the co-morbid condition.
According to Prof R.K. Singh, medical superintendent (RCH), “Diabetes is the commonest comorbidity seen in patients at our centre, followed by hypertension. Patients with organ dysfunction, particularly lungs and kidneys, form the next big chunk.”
The pattern speaks for a national trend observed by the Union ministry of health and family welfare, which has come up with specific guidelines for management of Covid-19 patients having a history of diabetes.
“Diabetes affects each part of the body in different degrees and ways. Therefore, when the body is under attack by any infection, Covid-19 in this case, the management is as challenging as filling water in a bucket with several holes,” he said.
From today India to export COVID-19 vaccines to these countries.
The Ministry of External Affairs said India will supply COVID-19 vaccines to partner countries over the coming weeks and months in a phased manner keeping in view the domestic requirements.
India, one of the world’s leading drug makers, will start exporting vaccines for the novel coronavirus from today. The country will provide supplies of Covid-19 vaccines to Bhutan, Maldives, Bangladesh, Nepal, Myanmar and Seychelles under grant assistance. Shipments will be sent to Sri Lanka, Afghanistan and Mauritius as well on receipt of necessary regulatory clearances.
In a tweet, Prime Minister Narendra Modi said India is deeply honored to be a “long-trusted” partner in meeting the healthcare needs of the global community and that supplies of the vaccines to several countries will commence on Wednesday, and more will follow in the days ahead.
“In response to these requests, and in keeping with India’s stated commitment to using India’s vaccine production and delivery capacity to help all of the humanity fight the COVID pandemic, supplies under grant assistance to Bhutan, Maldives, Bangladesh, Nepal, Myanmar and Seychelles will begin from January 20,” it said.
The Bangladesh foreign ministry said it expected to receive a gift of two million doses on Thursday. The country of 160 million, which has yet to start its vaccination programme, has ordered a further 30 million doses, officials said.
The Oxford/AstraZeneca vaccine is widely viewed as their best option because the other two, manufactured by Pfizer/BioNTech and by Moderna, need to be stored at very low temperatures. WHO emergency authorization for the Astra-Oxford vaccine would additionally allow SII to begin supplying it to the WHO-backed COVAX initiative aimed at fairly distributing COVID-19 shots across the world.
India has already rolled out a massive coronavirus vaccination drive under which two vaccines, Covishield and Covaxin, are being administered to frontline health workers across the country. While Oxford-AstraZeneca’s Covishield is being manufactured by the Serum Institute, Covaxin is being produced by Bharat Biotech.
“In an ongoing effort, India will continue to supply countries all over the world with vaccines. This will be calibrated against domestic requirements and international demand and obligations, including under GAVI’s Covax facility to developing countries,” the MEA added. GAVI is a global vaccine alliance.